Your AI-Trained Oncology Knowledge Connection!
Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses an ongoing study exploring the optimal sequence of immunotherapy agents and targeted therapies for patients with melanoma.
The observed adverse events that have been associated with immunotherapy, especially immunotherapy combinations, have to be properly assessed against their clearly improved efficacy in patients with otherwise dismal prognosis from stage IV cancers.
A team of researchers take a retrospective look at the patterns of how, when, and to whom palliative options are presented to patients with metastatic breast cancer, as an approach for gaining insight on how to improve care for patients with late-stage, terminal cancers.
Renuka Iyer, MD, associate professor of Oncology, co-director, Liver and Pancreas Tumor Center, section chief for Gastrointestinal Oncology, Roswell Park Cancer Institute, assistant professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, discusses treatment of patients with lung neuroendocrine tumors.
Roswell Park Cancer Institute is taking the final steps toward what we believe would be the first-ever clinical trial combining two novel and highly promising techniques: adoptive cellular therapy utilizing re-engineered mature T cells and re-engineered adult hematopoietic stem cells.
117-year-old facility is only comprehensive cancer center in Upstate New York
Philip McCarthy, MD, explains the significance of the updated CALGB 100104 study results.
Insurance plans that limit which doctors have in-network status have become a mainstay of healthcare, helping keep costs down but stoking concerns and complaints from hospital administrators and regulators about patients' access to care.
The FDA has approved subcutaneous omacetaxine mepesuccinate injection for home administration in patients with chronic or accelerated phase CML who are resistant or intolerant to treatment with TKIs.
So many new agents for the treatment of men with castration-resistant prostate cancer (CRPC) have been introduced in the past several years that optimal sequencing of therapies remains an unsettled question.
Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses eye toxicity from MEK inhibitors.
Meir Wetzler, MD, Chief, Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, discusses a study presented at the 2012 American Society of Hematology Meeting analyzing arsenic trioxide in acute promyelocytic leukemia.
James Mohler, MD, Roswell Park Cancer Institute, explains the progress needed to better understand androgen receptors.
A deeper understanding of androgen receptor signaling in castration-resistant prostate cancer has created an opportunity to deliver more effective therapies earlier in the treatment timeline.
Lenalidomide used continuously after autologous hematopoietic stem cell transplantation significantly prolonged the time to disease progression and overall survival in patients with multiple myeloma.
Dr. James Mohler, from Roswell Park Cancer Institute, Discusses the Need for Intermediate Endpoints for Early Stage Prostate Cancer Trials.
The investigational compound tasquinimod significantly postpones disease progression and increases PFS in men with minimally symptomatic, metastatic CRPC.
Founded in 1898 by Dr Roswell Park, Roswell Park Cancer Institute (RPCI) is the oldest dedicated comprehensive cancer center in the country
The National Comprehensive Cancer Network (NCCN) has issued new practice guidelines for managing certain patients with prostate cancer.